Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...
Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback